Combination Immunotherapy and Chemotherapy Used in GI Cancers

This roundtable series explores combination treatments for patients with upper gastrointestinal cancer, as discussed by key opinion leaders and participants at virtual live events.

CheckMate 649 Study in GI Cancers Shows Survival Benefit for Nivolumab/Chemotherapy

October 31st 2022

Jaffer A. Ajani, MD, discusses the design and results of the CheckMate 649 study of nivolumab, ipilimumab, and chemotherapy for gastric cancers.

Managing Adverse Events of Nivolumab/Chemotherapy for Gastric/GEJ Cancers

November 18th 2022

During a Targeted Oncology case-based roundtable event, Syma Iqbal, MD, discussed with participants their impressions of the CheckMate 649 chemoimmunotherapy regimen for patients with gastric/gastroesophageal junction cancers. This is the first of 2 articles based on this event.